More than solid – Roxolid®.
Increasing patient acceptance and offering more treatment options through smaller and stronger implants.
Roxolid® is a high performance alloy, specifically designed to offer higher strength than pure titanium and excellent osseointegration capabilities. Roxolid® offers more treatment options with smaller and stronger implants.
- Increase patient treatment acceptance
- More treatment options
- Ground breaking material
- Validated clinical performance
- Roxolid® Lifetime Plus Guarantee
Increase patient acceptance with less invasive treatment plans.
Dental implants are a well-established and predictable treatment option to replace missing teeth. Nevertheless, many patients are reluctant to face an implant treatment and are apprehensive if they require a bone augmentation procedure.
Avoiding invasive grafting procedures with Roxolid® offers numerous benefits:1,2
- Minimize patient anxiety with shorter treatment times
- Faster healing and less post-operative discomfort with smaller and shorter implants
- Smaller-sized implants protect vital structures and vascularization
- Minimize the mental hurdle with lower treatment costs
Elke Z., Germany, received Roxolid® implants five years ago.
"I was afraid that bone would have to be transplanted. The implant I have now, was like a gift for me."
More treatment options with small diameter and shorter Implants.
Straumann® Bone Level
titanium Ø 4.1 mm
Straumann® Bone Level
Roxolid® Ø 3.3 mm
Roxolid® reduced-diameter implants offer more treatment options with smaller and stronger implants. You can offer your patients a solution designed to fit to their individual needs.4
- More indications with Roxolid® Ø 3.3 mm implants*:
– Single tooth restorations in the anterior and premolar region
– Bridges on two Roxolid® Ø 3.3 mm Implants
– Full denture on two Roxolid® Ø 3.3 mm Implants
- Multiple advantages of Roxolid® reduced diameter implants**:
– Reduced drilling – preserve vital structures and vascularization
– Easier placement – saving time and patient discomfort
– Better fit in narrow spaces – leading to reduced treatment complexity
* compared to Straumann titanium Ø 3.3 mm implants / ** compared to their regular-diameter counterparts
Standard length SLActive®
Titanium Implant 4 mm Short
Straumann® has also developed a Roxolid® 4 mm short implant, the shortest screw-type implant with internal connection on the market. This provides even more treatment options.
- Perfectly suitable for the treatment of partially and fully edentulous patients with very limited vertical bone availability in the posterior region.
- Possibility to treat patients without complex vertical bone augmentations.
Ground breaking material. Stronger than titanium.
Higher tensile strength9
Roxolid® is a metal alloy composed of 15 % zirconium and 85 % titanium. The combination of these two metals leads to a material with a higher tensile and fatigue strength than comparable titanium implants.
Standard titanium grade 4 Straumann® titanium grade 4 Straumann® Roxolid®
Incremental fatigue strength per implant type10
Roxolid® SLActive® (Ø 3.3 mm) Implants show a higher fatigue strength in comparison to titanium SLActive® Implants.
Higher fatigue strength of Roxolid® SLActive®
BL NC = Bone Level Implant Narrow Crossfit®
BLT NC = Bone Level Tapered Implant Narrow Crossfit®
TL RN S = Tissue Level Regular Neck Standard Implant
TL RN SP = Tissue Level Regular Neck Standard Plus Implant
TL RN TE = Tissue Level Regular Neck Tapered Effect Implant
Validated clinical performance. Results you can rely on.
The successful use of Roxolid® implants has been documented in numerous clinical indications.6
There was no statistically significant difference between the crestal bone level changes for Roxolid® compared to titanium implants five years after implant placement.
Randomized Multi-Center study with 5 years follow-up.2
Roxolid® Lifetime Plus Guarantee. Our quality. Your assurance.
We have so much confidence in the quality and durability of every Roxolid® implant, that we offer an industry leading guarantee:
- Covers implant and part of the treatment costs
- Sets new standards
1 Al-Nawas B et al. (2012). Clin Implant Dent Relat Res 14(6):896-904. 2 Müller F et al. (2015). BMC Oral Health. 2015 Oct 12;15(1):123.
3 Quirynen M et al. (2015). Clin Oral Implants Res. Jul;26(7):831-40. 4 Altuna P et al., (2016). Int. J. Oral Maxillofac. Surg; in press. http://dx.doi.org/10.1016/j.ijom.2016.01.004 5 Schwarz F et al., (2007); J Periodontol 78(11):2171-2184. 6 www.straumann.com/science-roxolid 7 Gottlow J et al., (2012); Clin Implant Dent Relat Res 14 Suppl 1:e204-e212. 8 Wen B et al., (2014); Clinical Oral Implants Research. Jul;25(7):819-25. 9 Bernhard N et al., (2009). Forum Implantologicum 5(30). 10 Data on file 11 www.straumann.com/science-slactive